Earnings Call Insights: Neurocrine Biosciences (NBIX) Q1 2026
Management View
- CEO Kyle Gano said Q1 marked a commercial milestone: “For the first time in Neurocrine’s history, quarterly net product sales exceeded $800 million, representing 44% year-over-year growth,” adding the results were “primarily driven by INGREZZA” and that the
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.